Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma

[1]  Luya Wang,et al.  Metabolomic Approach to Screening Homozygotes in Chinese Patients with Severe Familial Hypercholesterolemia , 2023, Journal of clinical medicine.

[2]  A. D’Andrea,et al.  Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer. , 2022, Cancer discovery.

[3]  M. Trauner,et al.  Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology , 2022, Nature Reviews Gastroenterology & Hepatology.

[4]  M. Khan,et al.  Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma , 2022, World journal of gastroenterology.

[5]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[6]  D. Cui,et al.  Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma , 2021, Frontiers in Medicine.

[7]  M. Simon,et al.  Moonlighting functions of metabolic enzymes and metabolites in cancer. , 2021, Molecular cell.

[8]  J. Ji,et al.  A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation , 2021, Frontiers in Molecular Biosciences.

[9]  K. Meier,et al.  Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special? , 2021, Cells.

[10]  Chien-Chin Chen,et al.  Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials , 2021, Cells.

[11]  M. Mcphail,et al.  Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation , 2021, Hepatology.

[12]  Qiang Zhang,et al.  Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study , 2021, World journal of gastroenterology.

[13]  M. Mcphail,et al.  Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation , 2021, Hepatology.

[14]  Suwen Zhao,et al.  Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis , 2021, EBioMedicine.

[15]  Zeping Hu,et al.  Metabolomics, metabolic flux analysis and cancer pharmacology. , 2021, Pharmacology & therapeutics.

[16]  S. Imbeaud,et al.  Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma , 2021, Gut.

[17]  Mona Singh,et al.  Metabolite discovery through global annotation of untargeted metabolomics data , 2021, Nature Methods.

[18]  Q. Lei,et al.  Metabolite sensing and signaling in cancer , 2020, The Journal of Biological Chemistry.

[19]  Xiang Chen,et al.  The mechanisms of lysophosphatidylcholine in the development of diseases. , 2020, Life sciences.

[20]  Hwai I. Yang,et al.  Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis , 2019, European journal of gastroenterology & hepatology.

[21]  Dachao Li,et al.  Multi-marker Diagnosis Method for Early Hepatocellular Carcinoma Based on Surface Plasmon Resonance. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[22]  V. Aidinis,et al.  Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer , 2019, Cancers.

[23]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.

[24]  A. Quaglia.  Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist , 2018, Journal of hepatocellular carcinoma.

[25]  J. Locasale,et al.  Revisiting the Warburg Effect: Some Tumors Hold Their Breath. , 2018, Cell metabolism.

[26]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[27]  Ni Li,et al.  Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma , 2018, Cancer management and research.

[28]  Wei Jia,et al.  Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis , 2018, Nature Reviews Gastroenterology & Hepatology.

[29]  Xin Lu,et al.  A Large‐scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma , 2018, Hepatology.

[30]  Silvia Anahi Valdés-Rives,et al.  Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development , 2017, Mediators of inflammation.

[31]  Choon Nam Ong,et al.  Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma. , 2016, Cancer research.

[32]  Wei Jia,et al.  Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. , 2016, Journal of proteome research.

[33]  C. Bréchot,et al.  Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma , 2016, PloS one.

[34]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[35]  Xin Lu,et al.  Nontargeted modification-specific metabolomics study based on liquid chromatography-high-resolution mass spectrometry. , 2014, Analytical chemistry.

[36]  Z. Lou,et al.  NMR and LC/MS‐based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis , 2014, International journal of cancer.

[37]  Xi-jun Wang,et al.  Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma , 2013, Hepatology.

[38]  Thaer Barri,et al.  UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: effect of experimental artefacts and anticoagulant. , 2013, Analytica chimica acta.

[39]  F. Mach,et al.  Alpha-fetoprotein: a controversial prognostic biomarker for small hepatocellular carcinoma. , 2013 .

[40]  Xin Lu,et al.  Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. , 2012, Journal of proteome research.

[41]  Mahlet G Tadesse,et al.  Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. , 2012, Analytica chimica acta.

[42]  Jingmin Zhao,et al.  Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early Hepatocellular carcinoma in patients with cirrhosis , 2012, Journal of Hematology & Oncology.

[43]  Lanjuan Li,et al.  Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. , 2011, Analytica chimica acta.

[44]  Nguyen Dang Hung,et al.  Anti-inflammatory action of arachidonoyl lysophosphatidylcholine or 15-hydroperoxy derivative in zymosan A-induced peritonitis. , 2009, Prostaglandins & other lipid mediators.

[45]  J. Marrero,et al.  Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[46]  H. Bernstein,et al.  Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis , 2008, Clinical and experimental gastroenterology.

[47]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[48]  Peng Gao,et al.  High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. , 2006, Journal of proteome research.

[49]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.